Forteo (teriparatide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGE	
MEMBER INFORMATION	V			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP	CODE:	
PATIENT INSURANCE ID	NUMBER:			
MALE FEMALE	HEIGHT (IN/CM):	WEIGHT (LB/KG): A	LLERGIES:	
		PHI DISCLOSURE AUTHORIZATION FORM WITH	THIS REQUEST WHICH CAN BE FOUND AT THE	
OLLOWING LINK: PRIMETHERAPEUTIC	S.COM/NOPP			
ATIENT'S AUTHORIZED	REPRESENTATIVE (IF APPLIC	ABLE):		
PRESCRIBER INFORMAT	ION			
LAST NAME:		FIRST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:	_	1		
CITY:		STATE: ZIP	STATE: ZIP CODE:	
REQUESTOR (if different than	prescriber):	OFFICE CONTACT PER	SON:	
REQUESTOR (if different than	prescriber):	OFFICE CONTACT PER	SON:	
	prescriber): CAL DISPENSING INFORMAT		SON:	
			SON:	
MEDICATION OR MEDIC		ION LENGTH OF	QUANTITY:	
MEDICATION OR MEDICATION NAME: DOSE/STRENGTH:	CAL DISPENSING INFORMAT FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
MEDICATION OR MEDICATION NAME:	FREQUENCY: RENEWAL	ION LENGTH OF	QUANTITY:	

Prime THERAPEUTICS*

Forteo (teriparatide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
 □ Osteoporosis associated with systemic gl □ Osteoporosis in a male (idiopathic or hyp □ Osteoporosis in a postmenopausal femal □ Severe osteoporosis □ Other Diagnosis □ ICD-10 C 3. REQUIRED CLINICAL INFORMATION	pogonadal) le		
PRIOR AUTHORIZATION.			
Has the patient had previous treatment	nt with Tymlos (abaloparatide)? 🗆 Yes	s 🗆 No	
Has the patient ever been treated w it If "No" to the above question, does the creatinine clearance (CrCl) < 35 mL/mi *Please provide documentation	e patient have reflux/GERD or severe r	enal disease, as defined by a	
-	at intolerance is not considered a treatr ndronate [Fosamax], Actonel, ibandrona ide documentation.	- ·	
☐ A decline in bone mineral density in	reatment failure with bisphosphonate of g/cm2 of ≥ 3% in the spine and/or hip bisphosphonate therapy (fracture mus	while on bisphosphonate therapy	
-	evious treatment with at least one bispliva], or zoledronic acid [Reclast])*? □	•	
Does patient have a diagnosis of sever documentation.	re osteoporosis with very high fracture	risk? ☐ Yes ☐ No Please provide	
Does patient have a very low T-score (provide documentation.	(eg, T-score of ≤-3.0) even in the absend	ce of fracture(s)? Yes No Please	
Does patient have a T-score of ≤-2.5 p	lus a fragility fracture? Yes No Plea	ase provide documentation.	
Does patient have severe or multiple	vertebral fractures? Yes No Please	provide documentation.	



Forteo (teriparatide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?			
Please note: Not all drugs/diagnosis are cover information is received.	red on all plans. This request may be denied unless all required		
ATTESTATION: I attest the information provide	ded is true and accurate to the best of my knowledge. I understand that designees may perform a routine audit and request the medical of the information reported on this form.		
Prescriber Signature or Electronic I.D. Verifica	ation: Date:		
you are not the intended recipient, you are hereby notif	ng this transmission contain confidential health information that is legally privileged. If fied that any disclosure, copying, distribution, or action taken in reliance on the contents seived this information in error, please notify the sender immediately (via return FAX)		

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP - 4201
P.O. Box 64811

St. Paul, MN 55164-0811

